Cognitive Behavioral Therapy and GLP-1: A Comprehensive Review
Cognitive behavioral therapy (CBT) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are two innovative approaches that have gained significant attention in recent years for their effectiveness in managing various health conditions, including obesity, type 2 diabetes, and mental health disorders. In this article, we aim to examine the pathological features between type 2 diabetes and dementia, GLP-1 central effects, and analyze the relevant literature about the effect of GLP-1 analogs on cognitive function of patients with type 2 diabetes but also without.
Understanding GLP-1 and Its Effects
GLP-1 is a naturally occurring hormone involved in appetite regulation, digestion, and insulin release. GLP-1 medications mimic this hormone by slowing gastric emptying, increasing satiety, reducing hunger and food cravings, and influencing reward pathways related to eating behavior.
The Role of GLP-1 in Mental Health
Research has shown that GLP-1RAs can have a significant impact on mental health, with studies suggesting that they may reduce cravings, improve mood, and aid in emotional regulation. Furthermore, GLP-1RAs have been found to modulate multiple cognitive domains, including reward and motivational processes relevant to obesity and substance use disorder, affective-related behaviors, and learning and memory.
